Related Experiment Video

Updated: Jun 12, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a

J Pander, H Gelderblom, T van der Straaten

    British Journal of Cancer
    |June 10, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
    08:15

    gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

    Published on: October 6, 2014

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    Related Experiment Videos

    Last Updated: Jun 12, 2026

    Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
    04:07

    Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

    Published on: February 24, 2023

    gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
    08:15

    gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

    Published on: October 6, 2014

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
    10:27

    Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

    Published on: July 25, 2020

    Related Concept Videos

    DNA Microarrays02:34

    DNA Microarrays

    Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...
    Nucleotide Excision Repair01:38

    Nucleotide Excision Repair

    DNA Distortion and Damage
    Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...

    Articles linked to this work by shared authors, journal, and citation graph.

    Prospective evaluation of genomics-guided off-label treatment.

    Nature·2026

    Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer.

    ESMO open·2026

    Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

    medRxiv : the preprint server for health sciences·2026

    Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population.

    ESMO real world data and digital oncology·2026

    A comprehensive assessment of the existing landscape of personalized cancer medicine in the European Union, on behalf of the PCM4EU consortium.

    ESMO open·2025

    PSMA expression and PSMA PET/CT imaging in metastatic soft tissue sarcoma patients, results of a prospective study.

    European journal of nuclear medicine and molecular imaging·2025

    Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments.

    British journal of cancer·2026

    SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways.

    British journal of cancer·2026

    Why early pathology input matters in biologically rich cancer trials.

    British journal of cancer·2026

    ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.

    British journal of cancer·2026

    Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.

    British journal of cancer·2026

    On-treatment core needle biopsy identifies early responders for axillary surgery de-escalation: results from a prospective cohort.

    British journal of cancer·2026

    Silencing GJB2 attenuates IL-1β-induced chondrocyte injury by activating Nrf2/HO-1 signaling and preserving mitochondrial function.

    Folia histochemica et cytobiologica·2026

    DPM2 promotes melanoma progression and serves as a prognostic factor.

    Melanoma research·2026

    Efficacy of combined atorvastatin and paromomycin in treating experimental cryptosporidiosis in immunosuppressed mice.

    QJM : monthly journal of the Association of Physicians·2026

    Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

    Cancer discovery·2026

    Purine nucleoside phosphorylase in breast cancer from metabolic regulation to targeted therapy: challenges and opportunities.

    RSC medicinal chemistry·2026

    Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

    Frontiers in medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us